Rufinamide

CNS Drugs

Volumn 20, Issue 9, 2006, Pages 751-760

  Deeks, Emma D ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 1A2; ETHINYLESTRADIOL; ETHOSUXIMIDE; LAMOTRIGINE; NORETHISTERONE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; SODIUM CHANNEL; TOPIRAMATE; TRIAZOLAM; TRIAZOLE DERIVATIVE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ATONIC SEIZURE; CLINICAL TRIAL; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPTIC STATE; FATIGUE; FEVER; FOCAL EPILEPSY; HEADACHE; HUMAN; LENNOX GASTAUT SYNDROME; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; NERVE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEIZURE; SOMNOLENCE; TONIC SEIZURE; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; SEIZURES; TRIAZOLES;

EID: 33748519527     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620090-00007     Document Type: Review

References (30)

1. Epilepsy information (children): Lennox-Gastaut syndrome [online]. Available from URL: www.epilepsy.org.uk/info/lennox.html [Accessed 2006 Jun 7]
2. Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol 2002 Jan; 17 Suppl. 1: S70-5
3. Delanty N, French J. Treatment of Lennox-Gastaut syndrome: current recommendations. CNS Drugs 1998 Sep; 10: 181-8
4. Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; (3): CD003277
5. The Epilepsy Foundation [online]. Available from URL: http://www.epilepsyfoundation.org/answerplace/Medical/seizures/types/ partialSeizures/index.cfm [Accessed 2006 Jun 8]
6. Ben-Menachem E, Henriksen O, Johannessen SI. Diagnosis and treatment of partial seizures. CNS Drugs 1999 Jan; 11: 23-39
7. Jain KK. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin Investig Drugs 2000 Apr; 9 (4): 829-40
8. McLean MJ, Schmutz M, Pozza M, et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons [abstract no. 3.062]. Epilepsia 2005; 46 Suppl. 8: 296. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-296. Plus poster presented at the 59th Annual American Epilepsy Society M6; Washington, DC
9. White HS, Schmutz M, Pozza M, et al. The anticonvulsant profile and tolerability of rufinamide in mice and rats [abstract no. 3.088]. Epilepsia 2005; 46 Suppl. 8: 305-6. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-6; Washington, DC
10. Marchand M, Critchley D, Nagy C, et al. The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis [abstract no. A785 plus poster]. Annual Meeting of the Population Approach Group in Europe; 2005 June 16-7; Pamplona
11. Critchley D, Fuseau E, Perdomo C, et al. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome [abstract no. 2.351]. Epilepsia 2005; 46 Suppl. 8: 209. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-209. Plus poster presented at the 59th Annual American Epilepsy Society M6; Washington, DC
12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350 (10): 1013-22
13. Waldmeier F, Gschwind HP, Rouan MC, et al. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers [abstract no. 6.60]. Epilepsia 1996; 37 Suppl. 5: 167
14. Cardot JM, Lecaillon JB, Czendlik C, et al. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos 1998 May; 19 (4): 259-62
15. Kalbag JB, White-van Logtenberg M, Yeh CM, et al. Rufinamide, a novel antiepileptic drug, does not alter the pharmacokinetics of a CYP1A2 substrate, olanzapine, in healthy adults [abstract]. Epilepsia 2000; 41 Suppl.: 150
16. Svendsen KD, Choi L, Chen BL, et al. Single-center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women [abstract no. 2.111]. Epilepsia 1998; 39 Suppl. 6: 59
17. Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res 1995 Dec; 12: 1878-82
18. Fuseau E, Critchley D, Perdomo C, et al. Population pharmacokinetic drug-drug interaction analyses of rufinamide studies in patients with epilepsy [abstract no. 2.356]. Epilepsia 2005; 46 Suppl. 8: 210-11. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-6; Washington, DC
19. Racine A, Rouan MC, Chang SW, et al. Population pharmacokinetics and drug-drug interactions of rufinamide in a multicenter, double-blind, randomized, placebo-controlled, 5-arm parallel trial in patients with partial seizures on up to three concomitant antiepileptic drugs [abstract]. Epilepsia 2000; 41 Suppl.: 149-50
20. Perucca E, Cloyd J, Critchley D. The pharmacokinetics of the new antiepileptic drug rufinamide [poster]. 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-6; Washington, DC
21. Data on file, Eisai Limited
22. Chang SW, Yeh CM, Van Logtenberg M, et al. A geriatric pharmacokinetic evaluation of rufinamide [abstract no. PIII-48]. Clin Pharmacol Ther 2000 Feb; 67: 154
23. Kapeghian JC, Madan A, Parkinson A, et al. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro [abstract no. 1.96]. Epilepsia 1996; 37 Suppl. 5: 26
24. Glauser TA, Kluger G, Sachdeo R, et al. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial [abstract no. LBS.001]. Neurology 2005 Mar 22; 64 Suppl. 1: 1826. Plus poster presented at the 57th Annual Meeting of the American Academy of Neurology; 2005 Apr 9-16; Miami Beach (FL)
25. Glauser T, Kluger G, Sachdeo R, et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract no. p1356]. Epilepsia 2005; 46 Suppl. 6: 408. Plus poster presented at the 26th International Epilepsy Congress; 2005 Aug 28-Sep 1; Paris
26. Elger C, Stefan H, Perdomo C, et al. Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures [abstract no. 1.201]. Epilepsia 2005 Oct; 46 Suppl. 8: 83-4. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-6; Washington, DC
27. Brodie MJ, Rosenfeld W, Vasquez B, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures [abstract no. 2.239]. Epilepsia 2005 Oct; 46 Suppl. 8: 171. Plus poster presented at the 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-171. Plus poster presented at the 59th Annual American Epilepsy Society M6; Washington, DC
28. Palhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001 Feb; 43 (2): 115-24
29. Krauss GL, Perdomo CA, Arroyo S. Short-term and long-term safety of rufinamide in adult and adolescent patients with partial seizures [poster]. 59th Annual American Epilepsy Society Meeting; 2005 Dec 2-6; Washington, DC
30. Aldenkamp AP, Alpherts WCJ. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006; 47 (7): 1153-9